Cancer research
Research from Westlake University has led to the development of machine learning models that significantly improve survival predictions for patients with prostate cancer bone metastases (PCBM). The study, published in Scientific Reports, found that the models achieved a high accuracy in predicting survival outcomes, with area under the receiver operating
Cancer
Researchers at UHN have made a groundbreaking discovery in cancer research, finding a molecule called circular RNA (circRNA) that drives the transformation of specific prostate and lung cancers into more aggressive, treatment-resistant forms. The study reveals a new potential therapeutic target for neuroendocrine prostate cancer (NEPC) and small cell lung
Cancer
Former Sky News presenter Dermot Murnaghan has shared his experiences with stage four prostate cancer, highlighting the importance of getting tested for the disease. Murnaghan, 67, attributed his delayed diagnosis to a lack of PSA testing, which he learned about privately through his production company. He emphasized the need for
Cancer
Former Sky News presenter Dermot Murnaghan, now 67, has shared his distressing experience of being diagnosed with stage four prostate cancer, which he believes could have been caught earlier if he had undergone more frequent PSA blood tests. The alarming diagnosis has become a "massive wake-up call" for
Cancer
Researchers at Universite Paris Cite have made a significant discovery in the fight against prostate cancer, a leading cause of cancer-related deaths among men worldwide. According to a recent study, a targeted therapy using lipid nanoparticles (LNPs) decorated with an anti-prostate-specific membrane antigen (PSMA) nanobody has shown enhanced and specific
Cancer
Adcentrx Therapeutics has announced that its antibody-drug conjugate, ADRX-0405, has received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of patients with gastric cancer. The STEAP1-targeting ADC demonstrated favorable preclinical results, including pharmacokinetics, safety, and efficacy in animal models. The agent is currently being
Cancer research
Prostate cancer remains a significant health issue in the United States, with biomarkers offering a promising solution for risk stratification and guiding treatment decisions. While PSA screening improves early detection, it also leads to over-diagnosis and over-treatment. Researchers at Vanderbilt University Medical Center have examined the cost-effectiveness of serum, urine,
Cancer research
Researchers from Northeastern University in Shenyang, People's Republic of China, have proposed a novel model for classifying prostate cancer lymph node metastasis using dual-tracer PET/CT images. The model, MECF-Net, integrates 18F-PSMA-1007 and 18F-FDG PET/CT images to enhance feature perception and spatial dimensions. This research has the
Cancer research
Recent research on prostate cancer has shed light on the relationship between positive surgical margins (PSMs) and biochemical recurrence (BCR) in patients undergoing radical prostatectomy (RP). A study conducted in Kaohsiung, Taiwan, analyzed a cohort of 111 patients who underwent RP between 2011 and 2020. The researchers found that patients
Cancer research
Researchers at the University of Washington have made a significant discovery in the field of prostate cancer treatment, reporting promising results from a clinical trial combining a cancer vaccine with an immune checkpoint inhibitor. The study, published in the Journal for ImmunoTherapy of Cancer, found that the combination therapy led
Cancer research
Researchers at Miami University have made a significant discovery in the field of prostate cancer treatment. According to a recent study, the imidazoquinoline glycoconjugate BAIT628 has been found to exhibit significant efficacy and tolerability in treating prostate cancer. The study, published in the journal Pharmaceuticals, evaluated the safety and efficacy
Prostate cancer
A recent study conducted by researchers at the Institute of Cancerology aimed to analyze the distinct relapse patterns of hypofractionated radiation therapy (HFRT) versus conventionally fractionated radiation therapy (CFRT) in patients with intermediate-risk prostate cancer (PCa). The study, published in the International Journal of Radiation Oncology*Biology*Physics, utilized data
